Frankfurt
24.04.26 | 15:25
28,400 Euro
+3,65 % +1,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 28,600 | 29,000 | 25.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| Mo | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | Nanobiotix S.A.: Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology | 96 | GlobeNewswire (Europe) | Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle("LNP")-delivered therapies related to rapid liver clearancePre-treatment... ► Artikel lesen | |
| 07.04. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) | ||
| 02.04. | Nanobiotix stock price target raised to $36 by Guggenheim on NSCLC outlook | 4 | Investing.com | ||
| 01.04. | Fortschritte in der Pipeline: Leerink hebt Kursziel für Nanobiotix deutlich an | 2 | Investing.com Deutsch | ||
| 01.04. | Leerink raises Nanobiotix stock price target on pipeline progress | 3 | Investing.com | ||
| 31.03. | Nanobiotix GAAP EPS of -€0.50, revenue of €29.6M | 3 | Seeking Alpha | ||
| 31.03. | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results | 190 | GlobeNewswire (Europe) | Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck... ► Artikel lesen | |
| 30.03. | Nanobiotix im Fokus: Quartalszahlen als Bewährungsprobe für Krebs-Nanotechnologie | 5 | Investing.com Deutsch | ||
| 30.03. | Nanobiotix S.A.: NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | 9 | GlobeNewswire (USA) | ||
| 26.03. | Nanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026 | 3 | GlobeNewswire (USA) | ||
| 25.03. | Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process | 3 | Benzinga.com | ||
| 25.03. | Nanobiotix Clarifies About Recent Media Speculations Regarding Potential Takeover, Stock Up | 2 | RTTNews | ||
| 25.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.03. | Nanobiotix S.A.: NANOBIOTIX Statement Regarding Recent Media Speculation | 929 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches... ► Artikel lesen | |
| 25.03. | Nanobiotix-Aktie springt nach Bericht über mögliches Übernahmeinteresse von J&J | 20 | Investing.com Deutsch | ||
| 25.03. | Nanobiotix gains after report on J&J buyout bid | 5 | Seeking Alpha | ||
| 12.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 12.03. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 12.03. | Nanobiotix stock maintains Buy rating at TD Cowen on trial outlook | 2 | Investing.com |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 21,860 | +4,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,480 | -0,67 % | Cosciens Biopharma Inc: Cosciens Biopharma to exit U.S. reporting | ||
| HALOZYME THERAPEUTICS | 55,60 | -0,32 % | HALOZYME THERAPEUTICS, INC. - 8-K, Current Report | ||
| ABCELLERA BIOLOGICS | 3,545 | 0,00 % | Truist reiterates Buy on AbCellera stock ahead of 2H26 data | ||
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow | Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 245,00 | 0,00 % | BIO-RAD LABORATORIES, INC. - 8-K, Current Report | ||
| AVID BIOSERVICES | - | - | Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California | COSTA MESA, Calif., Feb. 24, 2026 /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state... ► Artikel lesen | |
| BIOLINERX | 1,720 | +3,61 % | BioLineRx Ltd.: BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers
GLIX1 has demonstrated potent... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,680 | +6,36 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 | MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets
MUC16 is highly and stably expressed in the most... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 5,530 | -1,43 % | Minerva Neurosciences, Inc: Minerva Announces Leadership Transition | Jim O'Connor joins as Chief Business Officer and General CounselBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| OVID THERAPEUTICS | 2,300 | +2,68 % | H.C. Wainwright bestätigt Kaufempfehlung für Ovid Therapeutics | ||
| COCRYSTAL | 1,240 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus | Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,077 | 0,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 6,400 | +6,31 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen |
NANOBIOTIX SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,65 % bei einem Aktienkurs von 28,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.